As per the terms of the deal, Orion will license the Chinese marketing rights of these two drugs to Eisai.
Eisai will distribute the drugs through its Chinese subsidiary, Eisai China.
Fareston, which contains the active substance toremifene, is used to treat hormone-dependent metastatic breast cancer in women who have been through the menopause.
Eldepryl is used in conjunction with levodopa-containing agents for the treatment of Parkinson’s disease in patients who have previously had an inadequate response when treated with levodopa therapies alone.